A brain mechanism has been discovered by researchers that may significantly advance our knowledge of sleep disorders and how to treat them. The Journal of Neuroscience published a study from McGill University and the University of Padua that provided insight into melatonin MT1, a key brain receptor that controls rapid eye movement (REM) sleep.

The REM sleep phase is linked to both vital brain activities and vivid dreams. This brain receptor offers intriguing clinical potential and contributes to a deeper knowledge of the sleep mechanism.

The "blue spot," sometimes referred to as the locus coeruleus, is a tiny but crucial area of the brain that was the focus of the study. This region is involved in the synthesis of noradrenaline, a neurotransmitter that helps us stay awake and attentive. This area of the brain becomes dormant during REM sleep, enabling us to transition into a dream state.

The duration of sleep can be effectively extended by current sleep therapies. However, they interfere with REM sleep. Since REM sleep is essential for memory consolidation and emotional processing, it is critical for preserving overall brain health.

REM sleep disturbances frequently have the potential to trigger major brain illnesses such as Lewy body dementia and Parkinson's disease. Finding the link between REM sleep and the MT1 receptor opens new therapeutic options for sleep disorders.